Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
October 12 2021 - 7:30AM
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech
company with a differentiated, small-molecule approach to treating
inflammatory conditions and diseases by selectively targeting the
resident microbiome to restore gut-immune homeostasis, today
announced that CEO Dan Menichella will present a company overview
at the Jefferies Virtual Next Generation IBD Therapeutics Summit at
1:45PM ET on Tuesday, October 19.
The webcast of the presentation will be made available in the
Investors & Media section of Kaleido’s website
at https://investors.kaleido.com/events-presentations. An
archived replay will be available for 30 days following the
event.
About Kaleido BiosciencesKaleido
Biosciences is a clinical-stage biotech company with a
differentiated, small-molecule approach to treating inflammatory
conditions and diseases by selectively targeting the resident
microbiome to restore gut-immune homeostasis. The Company has built
a proprietary product platform to enable the rapid and
cost-efficient discovery and development of novel Microbiome
Metabolic Therapies (MMT™). MMTs are designed to modulate the
metabolic output and profile of the microbiome by driving the
function and distribution of the gut’s existing microbes. Kaleido
is advancing a broad pipeline of MMT candidates with the potential
to address a variety of diseases and conditions with significant
unmet patient needs. To learn more,
visit https://kaleido.com/.
Contacts:
Kaleido BiosciencesWilliam Duke, Jr.Chief
Financial Officer617-890-5772william.duke@kaleido.com
Investors and MediaKotaro YoshidaArgot
Partners212-600-1902kaleido@argotpartners.com
Kaleido Biosciences (NASDAQ:KLDO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Kaleido Biosciences (NASDAQ:KLDO)
Historical Stock Chart
From Aug 2023 to Aug 2024